Herbalife Launches Bioniq GO in US, Targets Personalised Nutrition Growth Strategy
Herbalife's US launch of Bioniq GO, a personalised micronutrient supplement, follows its $150 million acquisition of UK-based Bioniq, marking a strategic pivot into next-generation wellness via digital assessment and tailored formulations.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
Los Angeles, United States — 10 August 2026
Herbalife has formally launched Bioniq GO, a personalised daily micronutrient supplement, into the U.S. market, expanding its 'next-gen wellness' portfolio. This launch follows the earlier acquisition of UK-based personalised nutrition brand Bioniq for $150 million. Bioniq GO leverages a proprietary digital wellness assessment to tailor formulations, offering consumers one of 40 micronutrient blends, each containing up to 23 vitamins and minerals, based on individual lifestyle and nutritional needs.
This initiative represents a core component of Herbalife's innovation strategy, emphasising accessibility in personalised nutrition through the integration of scientific formulations, digital technology, and its established distributor network. The company's strategic investments extend beyond Bioniq to include Link BioSciences, focusing on genomic and biological insights, and Pruvit, known for ketone supplements, alongside its existing Life I/O healthspan brand introduced in late 2025. These moves collectively aim to deliver scalable personalised nutrition solutions, combining product development with digital health tools and human coaching.
Herbalife reported robust financial performance for Q2 2026, with net sales reaching $1.3 billion, a 5.4% year-over-year increase. Adjusted EBITA stood at $167 million, exceeding guidance when factoring out foreign exchange fluctuations. This financial strength is underpinned by a significant capital restructuring earlier in 2026, including a $1.45 billion senior secured refinancing. This refinancing is projected to generate approximately $45 million in annual cash interest savings, enhancing the company's financial flexibility and debt maturity profile. Despite a 'hold' rating downgrade from Wall Street Zen, Herbalife anticipates earnings growth of 12.31% next year, from $2.68 to $3.01 per share.
What this means for United Kingdom
UK manufacturers and brand owners should note the commercial implications of Herbalife's Bioniq acquisition. The £120 million (approx. $150m) purchase price for a personalised nutrition platform signals significant market value and investment appetite for data-driven customisation. UK-based contract manufacturers must prepare for increased demand for smaller batch sizes and complex, multi-ingredient formulations to support bespoke product lines. Brand owners in the UK could explore similar digital assessment tools to differentiate offerings, but face higher R&D costs and regulatory hurdles for health claims validation by the FSA and MHRA. Competition in the personalised nutrition sector will intensify, requiring greater transparency and scientific substantiation for product efficacy.
Herbalife CEO Stephan Gratziani highlighted the European launch of Bioniq concurrently with the U.S. rollout, underscoring the company's commitment to expanding its personalised nutrition vision across key markets.
This trend is being actively addressed by UK manufacturing partners including Supplement Factory.